Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cancer Detected Using Blood Test and Gene Sequencing

By LabMedica International staff writers
Posted on 10 Dec 2012
A test that combines the ability to detect cancer DNA in blood with genome sequencing technology could be used to screen for cancers, monitor cancer patients for recurrence, and find residual cancer left after surgery.

To develop the test, scientists at the Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA; www.hopkinskimmelcancercenter.org) took blood samples from late-stage colorectal and breast cancer patients and healthy individuals, and looked for DNA that had been shed into the blood. More...
Whole-genome sequencing technology was applied to DNA found in blood samples, allowing the investigators to compare sequences from cancer patients with those from healthy people. The scientists then looked for telltale signs of cancer in the DNA: dramatic rearrangements of the chromosomes or changes in chromosome number that occur only in cancer cells.

No signs of cancer-specific chromosome changes were found in the blood of healthy individuals, but the investigators found various cancer-specific alterations in the blood of all seven patients with colon cancer and three patients with breast cancer. Using specialized bioinformatic approaches, they were able to detect these alterations in a small fraction of the millions of DNA sequences contained in the blood sample.

"This approach uses the power of genome sequencing to detect circulating tumor DNA in the blood, providing a sensitive method that can be used to detect and monitor cancers," said Victor Velculescu, MD, PhD, professor of oncology and codirector of the Cancer Biology Program at Johns Hopkins.

A report describing the new approach appears in the November 28, 2012, issue of the journal Science Translational Medicine.

Prof. Velculescu said that additional research will focus on determining how the new test could help doctors make decisions on treating patients. For example, the blood test could identify certain chromosomal changes that guide physicians to prescribe certain anticancer drugs or decide patient enrollment in clinical trials for drugs that target specific gene defects. Currently, physicians use cellular material biopsied from the original tumor to make these decisions, but tumor material can often be inaccessible or unavailable.

Related Links:

Johns Hopkins Kimmel Cancer Center



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Pipette Calibration System
Artel PCS®
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.